FDA Approves Merck's New Adult Pneumococcal Vaccine Capvaxive

Capvaxive targets 21 strains, offering enhanced protection against invasive pneumococcal disease and pneumonia in adults.

Capvaxive is the first pneumococcal conjugate vaccine specifically designed for adults.
The vaccine covers serotypes responsible for 85% of invasive pneumococcal disease in adults 50 and older.
Clinical trials demonstrated superior immune response compared to existing vaccines like PPSV23 and Prevnar 20.
The vaccine is expected to reduce hospitalizations, fatalities, and healthcare costs associated with pneumococcal disease.
CDC's Advisory Committee on Immunization Practices will discuss eligibility criteria for the vaccine on June 27.